Latest Regulatory Filings News

Alicanto Minerals has acknowledged a late filing of a director’s interest notice, attributing it to an administrative oversight. The ASX has queried the delay, prompting the company to review its disclosure procedures.

Miramar Resources has completed its Tranche 1 share placement and secured a further $205,000 commitment from a director for Tranche 2, pending shareholder approval in early 2026.

Amplitude Energy has addressed an ASX query regarding the delayed filing of a director’s interest change, attributing it to an administrative oversight while affirming its compliance framework.

Elixir Energy Limited has responded to ASX concerns over a delayed director interest disclosure, attributing the lapse to administrative changes and reaffirming its compliance protocols.

St Barbara Limited has completed a compelling restart study for its Touquoy gold project in Nova Scotia, outlining a low-capital, near-term operation with robust economics and a positive permitting outlook.

Vulcan Steel Limited has explained the late filing of a director’s interest notice due to an administrative error and outlined steps to strengthen compliance. The company commits to enhanced reminders and board training to prevent future delays.

Group 6 Metals Limited has updated its quarterly cash flow report, excluding certain financing from working capital calculations, while confirming sufficient funding and forecasting improved operational cash flows.

BSP Financial Group has explained the late filing of a director’s shareholding change, attributing it to delayed confirmation from a financial advisor, while reaffirming its compliance policies.

Telix Pharmaceuticals has dosed the first patient in the randomized expansion phase of its pivotal ProstACT Global Phase 3 trial for TLX591, targeting advanced prostate cancer. The trial is expanding globally, with regulatory submissions underway in the US and Europe.

Scout Security has made significant strides toward merging with Roo Inc, secured $600,000 in fresh capital, and progressed a new Insurtech partnership, all while managing tight cash flow in the September quarter.

Island Pharmaceuticals has been granted a pivotal US patent extending protection for its antiviral drug Galidesivir as a Covid-19 treatment until 2042, reinforcing its strategic position in the antiviral market.

Anteris Technologies has secured regulatory green lights for its pivotal PARADIGM trial and raised $25.2 million in capital, advancing its innovative DurAVR® transcatheter heart valve towards commercialisation.